Seneca Biopharma, Inc. Announces Completion of Phase II Clinical Study in China for the Treatment of Ischemic Stroke
GERMANTOWN, Maryland, Sept. 10, 2020 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need, today announced that the last subject completed their final follow-up assessment in the Company's...
Seneca Biopharma Announces Results of Meeting with FDA Regarding the Design of Phase 3 Trial for NSI-566 in ALS
GERMANTOWN, Maryland, April 9, 2020 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq: SNCA), a clinical-stage biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need, today announced that the company held a Type C meeting with the Office of Tissues a...
Seneca Biopharma, Inc. Announces the Completion of Stem Cell Manufacturing Facility in China
GERMANTOWN, Maryland, April 3, 2020 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need, today announced the completion of its new cell manufacturing facility in Suzhou,China. The facilit...
Seneca Biopharma Announces Presentations at Both Sachs Associates 3rd Annual Neuroscience Innovation Forum & Biotech Showcase™ 2020
GERMANTOWN, Maryland, Jan. 10, 2020 /PRNewswire/ -- Seneca Biopharma, Inc., (NASDAQ: SNCA), a clinical-stage biopharmaceutical company developing novel treatments for diseases of unmet medical need, announced today thatSeneca's Executive Chairman,Ken Carter, will present at both Sachs Associates ...
